The Anthrax Treatment Market is developing steadily as healthcare organizations and government agencies continue to focus on preparedness, diagnosis, and effective management of anthrax infections. Anthrax is caused by Bacillus anthracis and can occur in different forms, including cutaneous, inhalation, gastrointestinal, and injection anthrax.

The market is supported by increasing awareness of anthrax risks, improvements in diagnostic technologies, and continued investment in treatment research. Governments and emergency preparedness organizations are also maintaining resources and treatment supplies to respond to potential outbreaks and biological threats.

Antibiotics represent an important part of the treatment landscape, while antitoxins and other therapeutic approaches are also being investigated. Pharmaceutical and biotechnology companies are working on improved therapies, vaccines, and diagnostic technologies to strengthen preparedness and patient care.

According to Wise Guy Reports, the market was estimated at approximately USD 0.8 billion in 2023 and USD 0.85 billion in 2024. It is projected to reach around USD 1.5 billion by 2032, representing a CAGR of approximately 7.3% during the forecast period.

North America remains an important regional market because of its healthcare infrastructure and government preparedness initiatives. Meanwhile, Asia-Pacific and other developing regions may create additional opportunities as healthcare investment and awareness increase.